Nilanjan Ghosh, MD
Medical Oncology · Charlotte, NCNPI 1205035466
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.5%. Reporting peaked in 2019 at $131,531 and has fallen 65.7% since, to $45,099 in 2025. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $1073.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$104K
- Gilead$89K
- AbbVie$47K
- Johnson & Johnson$37K
- Bristol Myers Squibb$36K
- Seagen Inc.$24K
- plus $173K from 27 others
Across 645 payments — averaging $9075.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.6M
- F. Hoffmann-la Roche AG$975K
- Bristol Myers Squibb$835K
- Pharmacyclics LLC, An Abbvie Company$787K
- E.r. Squibb & Sons, L.L.C.$701K
- TG Therapeutics, Inc.$353K
- plus $569K from 7 others
What the payments were for
- Consulting fees$266,42252%
- Speaking & faculty fees$175,51534%
- Travel & lodging$56,81111%
- Food & beverage$10,8302%
- Education$1900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $104,382 |
| Gilead(2 entities) | 96 | $89,241 |
| AbbVie | 61 | $46,578 |
| Johnson & Johnson | 26 | $36,681 |
| Bristol Myers Squibb | 39 | $35,645 |
| Seagen Inc. | 27 | $23,760 |
| Genentech, Inc. | 8 | $19,348 |
| Incyte Corporation | 14 | $18,148 |
| Janssen Global Services, LLC | 11 | $16,693 |
| ADC Therapeutics America, Inc. | 11 | $15,428 |
| E.r. Squibb & Sons, L.L.C. | 10 | $14,476 |
| Genentech USA, Inc. | 13 | $12,247 |
| Novartis | 6 | $7,546 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $6,791 |
| F. Hoffmann-la Roche AG | 8 | $6,588 |
| Verastem, Inc. | 9 | $6,360 |
| Genmab U.S., Inc. | 6 | $5,702 |
| Janssen Scientific Affairs, LLC | 13 | $5,670 |
| Aurobindo Pharma USA, Inc. | 7 | $4,844 |
| Epizyme, Inc. | 4 | $4,775 |
| Beigene USA, Inc. | 6 | $4,562 |
| TG Therapeutics, Inc. | 1 | $4,050 |
| Spectrum Pharmaceuticals Inc. | 10 | $3,687 |
| Eli Lilly | 1 | $3,600 |
| Merck | 3 | $3,449 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,175 |
| Beigene, Ltd. | 2 | $2,075 |
| Astrazeneca UK Limited | 1 | $2,055 |
| Adaptive Biotechnologies Corporation | 2 | $1,535 |
| Karyopharm Therapeutics Inc. | 1 | $1,274 |
| Beone Medicines USA, Inc. | 2 | $249 |
| Eisai Inc. | 1 | $106 |
| Secura Bio, Inc. | 1 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$509,767 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $7,424 |
| Acyclovir | 102 | $1,318 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charlotte
- David RizzieriCharlotte$714K
- Mohamed SalemCharlotte$396K
- Edward KimCharlotte$188K
- Kathryn MilehamCharlotte$110K
- Antoinette TanCharlotte$89K
- Jimmy HwangCharlotte$64K
- Ashley SumrallCharlotte$55K
- Obiageli OgbataCharlotte$26K
- Daniel CarrizosaCharlotte$20K
- Daniel HaggstromCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.